Gilead Stock News

This is the 22nd year I've published my top 10 stock picks.

3 Biopharma Stocks Displaying Relative Strength Heading Into 2022

GILD vs. VIR: Which Stock Is the Better Value Option?

Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

10 Dividend Growth Stocks For December 2021

Solid sales from Veklury cushion Gilead (GILD) in 2021 amid COVID-19. However, new oral antivirals in the market might hurt sales.

We explain why selling the cash-covered puts and covered calls is a safer choice and earns a high income. We will discuss how to formulate an options income strategy that's sustainable and repeatable.

Benjamin F. Edwards & Company Inc. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 30,214 shares of the biopharmaceutical companys stock after acquiring an additional 1,405 shares during the quarter. Benjamin F. Edwards & []

Heritage Wealth Advisors lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 122.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,814 shares of the biopharmaceutical companys stock after purchasing an additional 1,000 shares during the quarter. Heritage Wealth Advisors holdings []

Victory Capital Management Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.1% during the third quarter, HoldingsChannel reports. The firm owned 1,590,092 shares of the biopharmaceutical company’s stock after selling 374,703 shares during the period. Victory Capital Management Inc.’s holdings in Gilead Sciences were worth $111,068,000 as of its most recent […]

Waldron Private Wealth LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 59.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,820 shares of the biopharmaceutical companys stock after buying an additional 3,289 shares during the period. Waldron []

Independent Advisor Alliance lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,172 shares of the biopharmaceutical companys stock after selling 436 shares during the quarter. Independent Advisor Alliances []

Believe it or not, you don't have to pay a premium to plug into good, reliable growth.

Gilead Sciences (GILD) closed the most recent trading day at $72.48, moving +0.07% from the previous trading session.

Ben Emons, Medley Global Advisors, joins Closing Bell to discuss the health care sector and whether now's the time to buy.